Introduction
Aortic valve stenosis (AS), the most common valvulopathy among adults, 1 is characterized by inflammatory processes, extracellular matrix (ECM) remodelling and calcification, causing a narrowing of the valve and the consequential obstruction in the cardiac outflow. 2 Valvular interstitial cells (VIC) control the structure and function of the aortic valve. During AS progression, VIC differentiate into the pathological myofibroblast and osteoblast-like type of cell that promote inappropriate ECM remodelling and subsequent valve calcification. 2 In atherosclerosis, the extravasation of blood inside the lesion, intraplaque haemorrhage, triggers an inflammatory response, increases cell proliferation, and enhances proteolytic activities that lead to ECM remodelling and plaque rupture. 3 Two recent observational studies have described internal bleedings in the cusps of stenotic aortic valves. 4, 5 Although those studies associated intraleaflet haemorrhage with AS progression, 4 the possible pathophysiology of iron accumulation in the valve and the role of VIC have remained hitherto unexplored. The aims of this study are to identify valvular iron in relation to pathological changes associated with AS and the effects on VIC in terms of iron uptake and iron-induced responses. By a combination of observations in human aortic valves in relation to clinical characteristics as well as evaluation of iron-induced responses in VIC, the present study provides a first mechanistic insight into the role of iron accumulation in ECM remodelling and calcification and how VIC participate in the process.
Materials and methods
Clinical data are presented as jittered dot plots and experimental data as mean + SD. All statistical analyses were two-sided. Adjusted P-values are shown for multiple comparisons. Supplementary material online, Tables S1 and S2 display patient characteristics. Expanded methods are provided in the Supplementary materials online.
Results

Iron positivity according to tissue characteristics and diagnosis
The characteristics of aortic valve regions by degree of iron positivity, as determined by Perls' staining, are shown in Figure 1A . Iron positivity (Categories 1 and 2) detected in non-calcified tissue was 27.6%, which was significantly lower compared with calcified tissue, 60.5% (P ¼ 0.007). Furthermore, tissues derived from bicuspid stenotic valves exhibited a higher proportion of iron positivity, 59.4%, compared with tricuspid stenotic valves, 34.3% (P ¼ 0.039), with the most pronounced iron accumulation in calcified tissue, exhibiting an iron positivity of 82.4 and 42.9% for bicuspid and tricuspid stenotic valves, respectively (P ¼ 0.013). The number of observations is given in Supplementary material online, Table S3 .
Iron positivity associations with clinical characteristics and gene expression
Stratifying AS patients according to iron positivity revealed a positive association with the degree of valve calcification ( Figure 1A) . In addition, gene expression according to the histological classification of directly adjacent tissue was performed in valves derived from 26 patients and revealed an increase in the expression of osteopontin (OPN) and matrix metalloproteinase 9 (MMP9; Figure 1A ).
Tumour necrosis factor-a and transforming growth factor-b regulate iron transporters in valvular interstitial cells
In terms of mRNA and protein levels, tumour necrosis factor-a (TNF-a) increased divalent metal transporter 1 (DMT1) and decreased ferroportin 1 (FPN1). Transforming growth factor-b (TGF-b) decreased FPN1 but did not significantly alter DMT1. Neither TNF-a nor TGF-b significantly altered the expression of 
Ferroportin 1 expression is reduced in valvular interstitial cells obtained from stenotic valves
Valvular interstitial cells derived from stenotic valves exhibited significantly (n ¼ 3) lower mRNA levels of FPN1 compared with those derived from control valves (fold change: 0.48 + 0.14; P ¼ 0.022), whereas DMT1 mRNA levels remained similar in the two VIC populations (fold change: 0.93 + 0.17; P ¼ 0.67).
Valvular interstitial cells and iron
Perls' staining of VIC incubated for 72 h with Ferrous sulfate (FeSO 4 ; 100 mmol/L) revealed an intracellular blue staining ( Figure 1C) . Quantitative iron measurements revealed a significant and timedependent increase in intracellular iron concentrations in the presence of FeSO 4 ( Figure 1C ). FeSO 4 (0-200 mmol/L) did not affect cell viability (see Supplementary material online, Figure S1 ).
Changes in VIC mRNA levels (n ¼ 3) encoding components of iron storage, transport, and metabolism were evaluated in the presence of 100 mmol/L Figure S1 ).
Valvular interstitial cells incubated for 72 h with 100 mmol/L FeSO 4 exhibited significantly increased proliferation and reduced elastin production ( Figure 1C ).
Discussion
Three novel and important notions emerge from the present study. First, non-haem iron accumulates in AS in relation to the degree of calcification and is associated with an increased expression of genes that promote ECM remodelling and calcification. Second, VIC can take up and accumulate iron, and iron transporters are regulated by pathways with a major impact on AS pathophysiology. Third, iron induced VIC proliferation and decreased elastin production. Taken together, these results provide mechanistic insights and suggest potential pathways linking, for example, intraleaflet haemorrhage to a maladaptive response to injury and valvular calcification.
Using Perls' staining, the present study is the first report of non-haem-bound iron in human aortic valves. Previous studies have used either glycophorin A staining to identify haemorrhages within aortic valve leaflets 4, 5 or biochemical methods to determine total valvular iron content. 6 In the present study, iron positivity prevailed in calcified regions of stenotic aortic valves, albeit also being detected in non-calcified areas. These results were supported by an increased valvular calcification in iron-positive human stenotic aortic valves and by the finding that iron-containing valve regions exhibited increased expression of OPN and MMP9; genes involved in valve remodelling and calcification, suggesting that iron may induce AS progression.
The source of valvular iron may originate from intraleaftlet haemorrhages and haem metabolism by macrophages, which co-localize with extravasated erythrocytes in human aortic valves. Although incompletely explored in valvular pathologies, the clearance of erythrocytes by macrophages in human atherosclerotic lesions results in the release of free iron from phagocytes to the extracellular space through FPN1. 7 In further support of a connection between the observed iron positivity and intraleaflet haemorrhages, both are more common in leaflets derived from bicuspid than from tricuspid aortic valves as demonstrated in the present and previous 5 studies.
Certain limitations of the histological approach should be acknowledged. Using Perls' staining in sections rather than whole valves may underestimate iron positivity; however, the large number of analysed sections generated a comprehensive map while allowing gene expression measurements. The observational design of the histological part of the study precludes any conclusions as to the causality of the associations between calcification and iron. Therefore, we subsequently sought for potential mechanisms by which iron may be linked to the pathophysiology of AS.
The two cytokines TNF-a and TGF-b that promote the acquisition of VIC phenotypes associated with AS 2 induced differential effects on the expression levels of iron transporters. Both mRNA and protein levels of the iron-importer DMT1 were up-regulated by TNF-a. Interestingly, DMT1 transports free iron from the extracellular to the intracellular space. Other iron transporters, which mediate the uptake of iron in its haem-bound form, as haemoglobinhaptoglobin complexes or transferrin, were unaltered by cytokine treatment. These results indicate that the free-iron uptake may be preferentially inducible. Furthermore, both TNF-a and TGF-b almost abolished mRNA and protein levels of the iron-exporter FPN1, suggesting that a decreased iron export can also be induced.
In support of these results, VIC isolated from stenotic valves expressed significantly lower levels of FPN1 than those derived from non-calcified valves. Taken together, these results indicate that in the context of AS, VIC may acquire a phenotype that predisposes for both the uptake and accumulation of iron. One of the major findings of the present study is the discovery of a time-dependent free-iron uptake in VIC. In the presence of FeSO 4 , also ferritin subunits were up-regulated, indicating a self-regulated increased iron storage capacity. Consistent with these results, an increased expression of both ferritins occurs in a-actin positive regions of advanced atherosclerotic lesions; regions that also exhibited iron positivity. 8 These findings suggest that VIC and smooth muscle cells share the characteristics of an inducible iron storage under pathological conditions. Furthermore, we provide the first piece of evidence linking iron accumulation with increased VIC proliferation. In AS, the Wnt/ b-catenin pathway is a main driver of VIC proliferation, 9 and increased intracellular iron concentrations promotes Wnt/b-catenin signalling in other cell types. 10 In addition, VIC decreased elastin production in response to iron. This finding is in agreement with a previous publication in skin fibroblasts. 11 This decreased elastin production demonstrated in vitro and the increased levels of A. Laguna-Fernandez et al.
MMP9 demonstrated in human aortic valves, together with the wellestablished role of decreased elastin production and increased degradation in AS development, 12, 13 argue in favour of the potential effect of iron as a modifying element in the structure of the aortic valve that can promote AS progression. In summary, our study provides both observational support from human tissue analysis and mechanistic evidence that non-haem-bound valvular iron is associated with ECM remodelling and calcification in AS. In addition, we demonstrate that VIC can take up and accumulate iron, which affects the response to injury in terms of VIC proliferation and elastin production.
